Biolargo (BLGO) Director Granted 242,645 Options; Replacement Option Issued
Rhea-AI Filing Summary
Marshall Dennis E, a director of Biolargo, Inc. (BLGO), reported option grants on 09/30/2025. Two options to purchase common stock were acquired: 132,351 shares exercisable at $0.17 per share (expiring 09/30/2035) and 110,294 shares exercisable at $0.17 per share (expiring 09/30/2035). The first option replaces a previously issued option for 34,615 shares that expired unexercised; the replacement was made under the issuer’s Compensation Committee plan in lieu of $22,500 in services. The second option was issued as payment of $18,750 in board fees under the 2024 Equity Incentive Plan. Following the reported grants, beneficial ownership figures shown are 4,957,267 and 5,067,561 shares on the respective lines. The Form 4 was signed by attorney-in-fact John R. Browning on 10/02/2025.
Positive
- Director compensation delivered via equity preserves cash and aligns interests with shareholders
- Replacement option was approved by the Compensation Committee to rectify an expired grant
Negative
- Total potential dilution of 242,645 option shares exists if both grants are exercised
- Low exercise price of $0.17 may represent a favorable grant relative to market price
Insights
Director received equity-based compensation and a replacement option for an expired grant.
The filing shows the board compensates directors partly with stock options, including a replacement for an expired service-related option. That reflects use of equity to conserve cash and align director incentives with shareholders. The replacement of a previously expired option was authorized by the Compensation Committee, indicating internal governance approval.
Two option grants total 242,645 shares exercisable at $0.17, expiring in 2035.
The reporting person received 132,351 and 110,294 option shares at a $0.17 exercise price, issued as compensation for services totaling $40,250 in fees or replacement value. These grants increase potential share dilution if exercised; the filing lists updated beneficial ownership totals on each line which should be used to assess dilution versus outstanding shares.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option to Purchase Common Stock | 132,351 | $0.00 | -- |
| Grant/Award | Option to Purchase Common Stock | 110,294 | $0.00 | -- |
Footnotes (1)
- This Option was granted to Reporting Person to replace an option to purchase 34,615 shares that had been issued to compensate Reporting Person for $22,500 in services to the Issuer and had recently expired unexercised due to a discrepancy between the original exercise price and Issuer's current stock price, pursuant to plan adopted by the Issuer's Compensation Committee. Total reflects the expiration of options to purchase 34,615 shares that recently expired. This Option was issued to Reporting Person as payment for $18,750 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan.
